How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public telehealth company.

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

An example of its marketing success would be the recent Superbowl ad campaign, which reverberated through the entire healthcare industry. According to EDO, HIMS' Super Bowl ad drove 7.7x as much ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

Hims & Hers Health, Inc. (HIMS) shares rallied 5.7% in the last trading session to close at $34.75. This move can be attributable to notable volume with a higher number of shares being traded than ...

In this article, we are going to take a look at where Hims & Hers Health Inc (NYSE:HIMS) stands against other defensive stocks that are surging in 2025. Defensive stocks are surging as investors ...

A Costly Bet That Might Not Pay Off Hims went all-in on weight loss. It spent an estimated $16 million on a Super Bowl ad in February. Its total marketing costs ballooned to $678.8 million in 2024 ...

We recently published a list of 10 Stocks Lead Friday’s Charge. In this article, we are going to take a look at where Hims & Hers Health Inc. (NYSE:HIMS) stands against other stocks that lead ...